JPRN-UMIN000018455
Completed
未知
Therapeutic Efficacy Ratio and Symptom Improvement Effect of New Potassium Ion-Competitive Acid Blocker (P-CAB) - Therapeutic Efficacy Ratio and Symptom Improvement Effect of New Potassium Ion-Competitive Acid Blocker (P-CAB)
Ishihara Gastroenterology clinic0 sites20 target enrollmentJuly 28, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ishihara Gastroenterology clinic
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •The patient that a serious heart, liver, renal function disorder, a patient developing a malignant neoplasm, a gastrointestinal tract resection, stomach esophagus junction rebuilding art, a patient having the past of the straying neurolysis, the combination taboo medicine of VFT
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
The effect of topical semisolid formulation of metformin on severity and number of skin lesions in acne patients.Acne vulgaris.Acne vulgarisIRCT2017013132319N1Shiraz University of Medical Sciences20
Completed
Not Applicable
Analysis of factors affecting therapeutic efficacy in intestinal inflammatioinflammatory bowel diseaseJPRN-UMIN000009697Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine30
Completed
Not Applicable
Clinical Observation of the Therapeutic Efficacy of Fuzi Lizhong Decoction Combined with SOX Regimen Chemotherapy in Treating Advanced Gastric Cancer with Spleen-Stomach Deficiency-Cold SyndromeGastric CancerITMCTR2024000164Yichang Traditional Chinese Medicine Hospital
Active, not recruiting
Phase 1
POISE - Psoriatic Oligoarthritis Intervention with Symptomatic thErapyPsoriatic Arthritis (PsA) is an inflammatory arthritis. PsA is a highly heterogenous disease with a proportion of participants having mild non-progressive disease. Well validated prognostic factors in PsA can identify these Participants including number of active joints, systemic inflammation levels, radiographic damage and functional ability at presentation. There is little research addressing outcomes and treatment options for mild disease.MedDRA version: 20.0 Level: LLT Classification code 10037160 Term: Psoriatic arthritis System Organ Class: 100000004859Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2018-001085-42-GBniversity of Oxford60
Recruiting
Not Applicable
Pathological evaluation of the therapeutic effect of argon plasma coagulation in gastric low grade dysplasiaKCT0006250Chungnam National University Hospital100